Antibody-Drug Conjugate Benefits HER2-Low Breast Cancers
German Institute for Quality and Efficiency in Health Care (IQWiG)
Patients with HER2-low breast cancers were included in the clinical trial proving the efficacy of trastuzumab deruxtecan monotherapy